Comparison of Translate Bio Inc. (TBIO) and Spero Therapeutics Inc. (NASDAQ:SPRO)

Both Translate Bio Inc. (NASDAQ:TBIO) and Spero Therapeutics Inc. (NASDAQ:SPRO) are Biotechnology companies, competing one another. We will contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Translate Bio Inc. N/A 1399.78 108.27M -3.06 0.00
Spero Therapeutics Inc. 3.27M 53.51 45.83M -3.06 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Translate Bio Inc. and Spero Therapeutics Inc.

Profitability

Table 2 has Translate Bio Inc. and Spero Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Translate Bio Inc. 0.00% 208.7% -52.9%
Spero Therapeutics Inc. -1,401.53% -52.4% -47.8%

Liquidity

The Current Ratio and Quick Ratio of Translate Bio Inc. are 16.7 and 16.7 respectively. Its competitor Spero Therapeutics Inc.’s Current Ratio is 13 and its Quick Ratio is 13. Translate Bio Inc. can pay off short and long-term obligations better than Spero Therapeutics Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Translate Bio Inc. and Spero Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Translate Bio Inc. 0 0 2 3.00
Spero Therapeutics Inc. 1 0 0 1.00

Translate Bio Inc.’s upside potential currently stands at 211.65% and an $23 consensus price target. Spero Therapeutics Inc. on the other hand boasts of a $9 consensus price target and a -11.42% potential downside. The information presented earlier suggests that Translate Bio Inc. looks more robust than Spero Therapeutics Inc. as far as analyst belief.

Institutional & Insider Ownership

Translate Bio Inc. and Spero Therapeutics Inc. has shares owned by institutional investors as follows: 49.9% and 59.8%. Insiders owned roughly 19.6% of Translate Bio Inc.’s shares. Comparatively, Spero Therapeutics Inc. has 0.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Translate Bio Inc. 17.7% 26.07% -26.26% 0% 0% -26.13%
Spero Therapeutics Inc. -17.85% -22.13% -36.6% -41.77% -36.06% -42.81%

For the past year Translate Bio Inc.’s stock price has smaller decline than Spero Therapeutics Inc.

Summary

Translate Bio Inc. beats on 7 of the 10 factors Spero Therapeutics Inc.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.